版本:
中国

BRIEF-Ligand enters into worldwide omniab platform license agreement with Xcella Biosciences

May 30 Ligand Pharmaceuticals Inc

* Ligand enters into worldwide omniab® platform license agreement with xcella biosciences

* Under license, xcella will be able to use omnirat, omnimouse and omniflic platforms

* Ligand Pharmaceuticals - co is eligible to receive development, regulatory milestone payments, royalties for each product incorporating an omniab antibody

* Xcella will be responsible for all costs related to the omni programs Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐